Meloxicam

Catalog No.S1734 Batch:S173401

Print

Technical Data

Formula

C14H13N3O4S2
Molecular Weight 351.4 CAS No. 71125-38-7
Solubility (25°C)* In vitro DMSO 30 mg/mL (85.37 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Meloxicam is a selective COX inhibitor, used to relieve pain and fever effects.
Targets
COX [1]
In vitro Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. [1] Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture. [2]
In vivo Meloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model. [2] Meloxicam causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. Meloxicam significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. Meloxicam reduces general MMP activity at PIH 8 and 24 in horse. [3] Meloxicam- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. Meloxicam results in high numbers of neutrophils in ischemia-injured tissue of horse. [4] Meloxicam administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs. [5]

Protocol (from reference)

Customer Product Validation

Data from [Data independently produced by , , Oncology letters, 2017, 2198-2206]

Selleck's Meloxicam has been cited by 4 publications

Meloxicam inhibits STING phosphorylation and alleviates intracellular DNA-mediated autoimmune responses [ Cell Biosci, 2023, 13(1):76] PubMed: 37120570
Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway [ J Oncol, 2022, 2022:4598573] PubMed: 35237322
Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis. [ PLoS One, 2020, 13;15(3):e0230272] PubMed: 32168360
Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. [Iturriaga MP, et al. Oncol Lett, 2017, 14(2):2198-2206] PubMed: 28781660

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.